All In Biotech

Drug Trial Radar · NCT01261325

Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures

A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥16 to 80 Years Old) With Partial Onset Seizures

Last checked: Nov 20, 2026Latest source record: Jul 22, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 768 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

768

Actual

Start

Dec 2010

Primary completion

May 2014

Study completion May 2014

Sponsor

Lead sponsor
UCB PharmaUCB
Sponsor type
Industry
First posted
Dec 16, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 16 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy and safety of brivaracetam at doses of 100 and 200mg/day compared to placebo as adjunctive treatment in adult focal epilepsy subjects with partial onset seizures not fully controlled despite current treatment with 1 or 2 concomitant antiepileptic drugs.

Conditions

  • Epilepsy

Interventions

  • PlaceboDrug

    Daily oral dose of two equal intakes of placebo in a double-blinded way for the 12-week treatment period

  • BrivaracetamDrug

    Daily oral dose of two equal intakes of Brivaracetam 100 mg/ day in a double-blinded way for the 12-week treatment period

  • BrivaracetamDrug

    Daily oral dose of two equal intakes of Brivaracetam 200 mg/ day in a double-blinded way for the 12-week treatment period.

  • Antiepileptic drugs with market authorization available per countryDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Reduction Over Placebo for Partial Onset Seizure (Type I) Frequency Over the Treatment Period Standardized to a 28-day DurationTime frame: 12 week Treatment Period
  2. 50% Responder Rate for Partial Onset Seizure (Type I) Frequency Over the Treatment Period Standardized to a 28-day DurationTime frame: Baseline to 12 week Treatment Period

Locations

207 sites in 28 countries. Site status is shown where the registry gives one.

  • 001

    Phoenix, Arizona

  • 013

    Phoenix, Arizona

  • 006

    Tucson, Arizona

  • 775

    Little Rock, Arkansas

  • 045

    Sacramento, California

  • 025

    San Francisco, California

  • 060

    Aurora, Colorado

  • 085

    Colorado Springs, Colorado

  • 071

    Miami, Florida

  • 110

    Miami, Florida

  • 073

    Naples, Florida

  • 090

    Ocala, Florida

  • 027

    Orlando, Florida

  • 064

    Port Charlotte, Florida

  • 044

    Sarasota, Florida

  • 023

    Atlanta, Georgia

  • 063

    Atlanta, Georgia

  • 062

    Columbus, Georgia

  • 048

    Rome, Georgia

  • 039

    Boise, Idaho

  • 005

    Peoria, Illinois

  • 017

    Winfield, Illinois

  • 020

    Ames, Iowa

  • 069

    Iowa City, Iowa

  • 780

    Lexington, Kentucky

  • 092

    Hammond, Louisiana

  • 008

    Bethesda, Maryland

  • 068

    Waldorf, Maryland

  • 055

    East Lansing, Michigan

  • 009

    Golden Valley, Minnesota

  • 051

    Missoula, Montana

  • 032

    Lebanon, New Hampshire

  • 042

    Hamilton, New Jersey

  • 058

    Voorhees Township, New Jersey

  • 095

    Kingston, New York

  • 022

    New York, New York

  • 099

    New York, New York

  • 098

    Poughkeepsie, New York

  • 010

    Asheville, North Carolina

  • 003

    Durham, North Carolina

Showing 40 of 207 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.